Muscular dystrophy associated with α-dystroglycan deficiency in Sphynx and Devon Rex cats

Paul T. Martin, G. Diane Shelton, Peter J Dickinson, Beverly Sturges, Rui Xu, Richard A Lecouteur, Ling T. Guo, Robert A Grahn, Harriet P. Lo, Kathryn N. North, Richard Malik, Eva Engvall, Leslie A Lyons

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Recent studies have identified a number of forms of muscular dystrophy, termed dystroglycanopathies, which are associated with loss of natively glycosylated α-dystroglycan. Here we identify a new animal model for this class of disorders in Sphynx and Devon Rex cats. Affected cats displayed a slowly progressive myopathy with clinical and histologic hallmarks of muscular dystrophy including skeletal muscle weakness with no involvement of peripheral nerves or CNS. Skeletal muscles had myopathic features and reduced expression of α-dystroglycan, while β-dystroglycan, sarcoglycans, and dystrophin were expressed at normal levels. In the Sphynx cat, analysis of laminin and lectin binding capacity demonstrated no loss in overall glycosylation or ligand binding for the α-dystroglycan protein, only a loss of protein expression. A reduction in laminin-α2 expression in the basal lamina surrounding skeletal myofibers was also observed. Sequence analysis of translated regions of the feline dystroglycan gene (DAG1) in affected cats did not identify a causative mutation, and levels of DAG1 mRNA determined by real-time QRT-PCR did not differ significantly from normal controls. Reduction in the levels of glycosylated α-dystroglycan by immunoblot was also identified in an affected Devon Rex cat. These data suggest that muscular dystrophy in Sphynx and Devon Rex cats results from a deficiency in α-dystroglycan protein expression, and as such may represent a new type of dystroglycanopathy where expression, but not glycosylation, is affected.

Original languageEnglish (US)
Pages (from-to)942-952
Number of pages11
JournalNeuromuscular Disorders
Volume18
Issue number12
DOIs
StatePublished - Dec 2008

Fingerprint

Dystroglycans
Muscular Dystrophies
Cats
Laminin
Glycosylation
Skeletal Muscle
Sarcoglycans
Dystrophin
Felidae
Muscle Weakness
Muscular Diseases
Peripheral Nerves
Lectins
Basement Membrane
Sequence Analysis
Real-Time Polymerase Chain Reaction
Carrier Proteins
Proteins
Animal Models
Ligands

Keywords

  • Devon Rex
  • Dystroglycan
  • Feline
  • Glycosylation
  • Muscular Dystrophy
  • Neuromuscular
  • Sphynx

ASJC Scopus subject areas

  • Clinical Neurology
  • Pediatrics, Perinatology, and Child Health
  • Genetics(clinical)
  • Neurology

Cite this

Muscular dystrophy associated with α-dystroglycan deficiency in Sphynx and Devon Rex cats. / Martin, Paul T.; Shelton, G. Diane; Dickinson, Peter J; Sturges, Beverly; Xu, Rui; Lecouteur, Richard A; Guo, Ling T.; Grahn, Robert A; Lo, Harriet P.; North, Kathryn N.; Malik, Richard; Engvall, Eva; Lyons, Leslie A.

In: Neuromuscular Disorders, Vol. 18, No. 12, 12.2008, p. 942-952.

Research output: Contribution to journalArticle

Martin, Paul T. ; Shelton, G. Diane ; Dickinson, Peter J ; Sturges, Beverly ; Xu, Rui ; Lecouteur, Richard A ; Guo, Ling T. ; Grahn, Robert A ; Lo, Harriet P. ; North, Kathryn N. ; Malik, Richard ; Engvall, Eva ; Lyons, Leslie A. / Muscular dystrophy associated with α-dystroglycan deficiency in Sphynx and Devon Rex cats. In: Neuromuscular Disorders. 2008 ; Vol. 18, No. 12. pp. 942-952.
@article{ae0a9b79104e4b48a4d293936e289764,
title = "Muscular dystrophy associated with α-dystroglycan deficiency in Sphynx and Devon Rex cats",
abstract = "Recent studies have identified a number of forms of muscular dystrophy, termed dystroglycanopathies, which are associated with loss of natively glycosylated α-dystroglycan. Here we identify a new animal model for this class of disorders in Sphynx and Devon Rex cats. Affected cats displayed a slowly progressive myopathy with clinical and histologic hallmarks of muscular dystrophy including skeletal muscle weakness with no involvement of peripheral nerves or CNS. Skeletal muscles had myopathic features and reduced expression of α-dystroglycan, while β-dystroglycan, sarcoglycans, and dystrophin were expressed at normal levels. In the Sphynx cat, analysis of laminin and lectin binding capacity demonstrated no loss in overall glycosylation or ligand binding for the α-dystroglycan protein, only a loss of protein expression. A reduction in laminin-α2 expression in the basal lamina surrounding skeletal myofibers was also observed. Sequence analysis of translated regions of the feline dystroglycan gene (DAG1) in affected cats did not identify a causative mutation, and levels of DAG1 mRNA determined by real-time QRT-PCR did not differ significantly from normal controls. Reduction in the levels of glycosylated α-dystroglycan by immunoblot was also identified in an affected Devon Rex cat. These data suggest that muscular dystrophy in Sphynx and Devon Rex cats results from a deficiency in α-dystroglycan protein expression, and as such may represent a new type of dystroglycanopathy where expression, but not glycosylation, is affected.",
keywords = "Devon Rex, Dystroglycan, Feline, Glycosylation, Muscular Dystrophy, Neuromuscular, Sphynx",
author = "Martin, {Paul T.} and Shelton, {G. Diane} and Dickinson, {Peter J} and Beverly Sturges and Rui Xu and Lecouteur, {Richard A} and Guo, {Ling T.} and Grahn, {Robert A} and Lo, {Harriet P.} and North, {Kathryn N.} and Richard Malik and Eva Engvall and Lyons, {Leslie A}",
year = "2008",
month = "12",
doi = "10.1016/j.nmd.2008.08.002",
language = "English (US)",
volume = "18",
pages = "942--952",
journal = "Neuromuscular Disorders",
issn = "0960-8966",
publisher = "Elsevier Limited",
number = "12",

}

TY - JOUR

T1 - Muscular dystrophy associated with α-dystroglycan deficiency in Sphynx and Devon Rex cats

AU - Martin, Paul T.

AU - Shelton, G. Diane

AU - Dickinson, Peter J

AU - Sturges, Beverly

AU - Xu, Rui

AU - Lecouteur, Richard A

AU - Guo, Ling T.

AU - Grahn, Robert A

AU - Lo, Harriet P.

AU - North, Kathryn N.

AU - Malik, Richard

AU - Engvall, Eva

AU - Lyons, Leslie A

PY - 2008/12

Y1 - 2008/12

N2 - Recent studies have identified a number of forms of muscular dystrophy, termed dystroglycanopathies, which are associated with loss of natively glycosylated α-dystroglycan. Here we identify a new animal model for this class of disorders in Sphynx and Devon Rex cats. Affected cats displayed a slowly progressive myopathy with clinical and histologic hallmarks of muscular dystrophy including skeletal muscle weakness with no involvement of peripheral nerves or CNS. Skeletal muscles had myopathic features and reduced expression of α-dystroglycan, while β-dystroglycan, sarcoglycans, and dystrophin were expressed at normal levels. In the Sphynx cat, analysis of laminin and lectin binding capacity demonstrated no loss in overall glycosylation or ligand binding for the α-dystroglycan protein, only a loss of protein expression. A reduction in laminin-α2 expression in the basal lamina surrounding skeletal myofibers was also observed. Sequence analysis of translated regions of the feline dystroglycan gene (DAG1) in affected cats did not identify a causative mutation, and levels of DAG1 mRNA determined by real-time QRT-PCR did not differ significantly from normal controls. Reduction in the levels of glycosylated α-dystroglycan by immunoblot was also identified in an affected Devon Rex cat. These data suggest that muscular dystrophy in Sphynx and Devon Rex cats results from a deficiency in α-dystroglycan protein expression, and as such may represent a new type of dystroglycanopathy where expression, but not glycosylation, is affected.

AB - Recent studies have identified a number of forms of muscular dystrophy, termed dystroglycanopathies, which are associated with loss of natively glycosylated α-dystroglycan. Here we identify a new animal model for this class of disorders in Sphynx and Devon Rex cats. Affected cats displayed a slowly progressive myopathy with clinical and histologic hallmarks of muscular dystrophy including skeletal muscle weakness with no involvement of peripheral nerves or CNS. Skeletal muscles had myopathic features and reduced expression of α-dystroglycan, while β-dystroglycan, sarcoglycans, and dystrophin were expressed at normal levels. In the Sphynx cat, analysis of laminin and lectin binding capacity demonstrated no loss in overall glycosylation or ligand binding for the α-dystroglycan protein, only a loss of protein expression. A reduction in laminin-α2 expression in the basal lamina surrounding skeletal myofibers was also observed. Sequence analysis of translated regions of the feline dystroglycan gene (DAG1) in affected cats did not identify a causative mutation, and levels of DAG1 mRNA determined by real-time QRT-PCR did not differ significantly from normal controls. Reduction in the levels of glycosylated α-dystroglycan by immunoblot was also identified in an affected Devon Rex cat. These data suggest that muscular dystrophy in Sphynx and Devon Rex cats results from a deficiency in α-dystroglycan protein expression, and as such may represent a new type of dystroglycanopathy where expression, but not glycosylation, is affected.

KW - Devon Rex

KW - Dystroglycan

KW - Feline

KW - Glycosylation

KW - Muscular Dystrophy

KW - Neuromuscular

KW - Sphynx

UR - http://www.scopus.com/inward/record.url?scp=56949093730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56949093730&partnerID=8YFLogxK

U2 - 10.1016/j.nmd.2008.08.002

DO - 10.1016/j.nmd.2008.08.002

M3 - Article

C2 - 18990577

AN - SCOPUS:56949093730

VL - 18

SP - 942

EP - 952

JO - Neuromuscular Disorders

JF - Neuromuscular Disorders

SN - 0960-8966

IS - 12

ER -